Decision Maker Response

Sussan Ley’s response

Dec 18, 2015 — I wanted to let people know that I last night signed off Pharmaceutical Benefits Advisory Committee recommendation to now give patients 24 months access to Eculizumab before a clinical assessment is required to determine whether or not treatment should continue.

This ensures decisions are made without undue influence or pressure about whether a new medicine really will deliver what it promises patients for the price it costs.

This is the foundation behind the success of Australia’s world-class system for subsiding medicines and we support this process continuing.

I wish May and all sufferers of aHUS the very best with their ongoing treatment and best wishes for the festive season.

For more information on announcement: